Synthesis and characterization of 4-amino-4H-1,2,4-triazole derivatives: Anticonvulsant activity

Mallesha Lingappa*, Vinay Guruswamy and Veeresh Bantal

PG Department of Chemistry, JSS College of Arts, Commerce and Science, Ooty Road, Mysuru 570 025, India
Department of Pharmacology, G Pulla Reddy College of Pharmacy, Mehdipatnam, Hyderabad 500 028, India

ABSTRACT
A new series of 4-amino-4H-1,2,4-triazole derivatives, 3a-f and 5a-f were synthesized by using various aryl aldehydes and ketones. FT-IR, 1H NMR, 13C NMR and mass spectral studies were characteristic of the synthesized compounds. These new compounds were screened in male wistar rats and compared with the standard drug for their anticonvulsant activity against maximal electroshock seizure (MES) model. Compounds 3b and 5d of this sequence were found to be the most active. The same compound did not demonstrate neurotoxicity at the administered maximum dose (100 mg / kg) and these compounds showed good protection compared to other compounds.

1. Introduction
The heterocyclic compounds usually don’t easily get depolymerized or hydrolyzed contain a firm ring configuration. Heterocycles with three-atoms in the ring structure posses ring strain due to which they are more reactive. In general, those which contain one heteroatom are stable. Due to the biological importance and structural diversity of N-containing heterocycles for synthesis they are the most gorgeous targets over many years. N-heterocycles are utilized for food flavorings, medicines, dyes, rubber chemicals and adhesives. Searching for the new agent is the most difficult tasks for the medicinal chemist. Due to their usefulness in a variety of applications, the synthesis of high N-containing heterocyclic systems has attracted growing interest in the last decade, applications like explosives, propellants, pyrotechnics and particularly chemotherapy. Due to its wide range of activities, low toxicity, strong pharmacokinetic and pharmacodynamic profiles, 1,2,4-triazole has drawn considerable interest from the 1,2,4-triazole to medicinal chemists of two decades. The first 1,2,4-triazole is 3-amino-1,2,4-triazole and it was manufactured from aminoguanidine format on large scale, useful as herbicides. N-substituted triazole with another substituent and it showed biological activity such as anti-inflammatory, anticonvulsant, anticancer, antimycobacterial, antioxidant and antimalarial.
Imines act as backbones for the various heterocyclic compound syntheses. This is responsible for the biological activity due to the presence of functional groups of sulfonamides and azomethine and this can be altered according to the form of substituent present on the aromatic rings. It is used in replacement reactions and cycloaddition. Schiff bases with the nitro- and halo-derivatives showed biological activity. Several researchers studied to certain Schiff bases that bear aryl groups or heterocyclic residues that have had excellent biological activity in recent years. Particularly in 1,2,4-triazole and their heterocyclic derivatives have been testified to be used as drugs and to have significant activities properties. Therefore, it was thought meaningful to produce Schiff base substituted 1,2,4-triazoles derivatives.

The pharmacological approaches for treating epilepsy are intended to inhibit the initiation or spread of seizures rather than the underlying mechanisms leading to epilepsy. Some epileptic patients are unresponsive to current antiepileptic drug treatment, and for this reason the major goal in epilepsy research has been to develop drugs with greater anticonvulsant efficacy and less toxicity than existing drugs. There is an experimentally-induced seizure and leads to the increased susceptibility to seizures found in certain genetically-prone animals. The vast number of chemicals in industrial use not worked including animal health concerns to resolve problems associated with growing costs and time needed for neurotoxicity testing. Several in vitro models have been commonly used in neurotoxicity assessments, including synaptic fractions, rat astrocyte cultures and murine spinal cord cultures as neurotoxicity studies. The present paper reports in view of these findings, on the 1,2,4-triazole derivatives synthesis and distinguished by specific spectral studies. It was also confirmed that all the compounds had anticonvulsant activity.

2. Results and Discussion

The synthesized molecules (3a-f) and (5a-f) were identified using 13C NMR, 1H NMR, mass and infrared study. Table 1 showed structure of new molecules. The system outlined in the scheme was used to synthesize the Schiff bases. The physical details and UV-visible absorption spectra of 3a-f and 5a-f values are explained in experimental section. The reactants show in the ultraviolet absorption spectrum. Bathochromic shift occurs in products with the absorption band being located above 320 nm.

Table 1. Chemical structure of imines compound.

| Compound | R/R¹ | Structure |
|----------|------|-----------|
| 3a       | H/H  | ![Image](attachment:image1.png) |
| 3b       | Cl/Cl| ![Image](attachment:image2.png) |
| 3c       | OCH₃/OCH₃| ![Image](attachment:image3.png) |
The spectra of FT-IR run in FT-IR spectroscopy. The absorption of 1655-1600 cm\(^{-1}\) due to C=N function. All the compounds give an absorption in 3097-3032 cm\(^{-1}\) due to aromatic vibration peaks. The absence of amine and carbonyl group in FT-IR range supported the condensation of the new compounds. The changes in integral intensities and bandwidths, however, particularly of the bands originating from stretching vibrations of NH\(_2\) did not show in products (Fig. 1 and Fig. 2).

New compounds exhibited a singlet in \(\delta = 8.75-8.20\) ppm region due to triazole proton in the \(^1\)H NMR spectra. The aromatic doublet protons appeared between \(\delta = 7.95-6.10\) (Ar-H). A singlet was observed at \(\delta = 8.40\) to 8.10 ppm due to imines protons in 3a-f. A singlet was observed at \(\delta = 0.95-0.90\) ppm due to \(\text{CH}_3\) protons in 5a-f. \(^{13}\)C NMR is a commanding instrument to characterize new compounds. In products spectra one value for chemical shift is obtained, about 164.7-156 ppm for imines. The aromatic carbons represent the carbon atoms exact numeral at the appropriate chemical shift values at 160 to 106 ppm. Triazole carbons in the products appeared at 149 to 147 ppm. \(\text{CH}_3\) carbons in 5a-f showed chemical shift values at 16.8 to 13.0 ppm. The mass spectra showed molecular ion peak, which are concorded with molecular formula.

All the analogues of the synthesized triazoles were screened at 100 mg/kg dose for their anticonvulsant potential via MES model. For many decades, anti-epileptic drug research has focused on discovering new potential medicines based on their anticonvulsant action against single acute seizures that are triggered by multiple stimulators, typically in mice and rats. In MES model, all known antiepileptic drugs have anticonvulsant activity.\(^{19}\) It was shown that compounds 3b and 5d had a major protective effect on MES-induced and it was close to that of normal (phenytoin). Similarly, other compounds displayed modest protective effect and a substantial difference in safety relative to the standard group was observed. (Table 2, Fig. 3). Neurotoxicity was used for compounds 3a-f and 5a-f using a rotarod method given in 100 mg/kg dose. Both molecules did not exhibit toxicity although 3a and 5f demonstrated 25 percent toxicity according to the normal at 2 hours of oral administration (Table 3). The structure of standard drug phenytoin contains imidazole group with diphenyl ring and it exhibited 75.80 % protection in the anticonvulsant activity. The electron withdrawing halogen groups in 3b produces enhanced anticonvulsant activity against the tested rats. This indicates the positional
requirement of halogen groups on phenyl ring for enhanced activity. The indole group of 5d showed good anticonvulsant activity and these structural activity relationship studies reveal that, the nature of the functional groups is crucial for anticonvulsant activity.

### Table 2. In vivo anticonvulsant activity of compounds (3a-f) and (5a-f).

| Compound | E/F | % Protection |
|----------|-----|--------------|
| 3a       | 3.76| 20.10        |
| 3b       | 1.67| 64.42        |
| 3c       | 3.39| 28.00        |
| 3d       | 3.19| 32.36        |
| 3e       | 3.20| 32.20        |
| 3f       | 3.29| 30.15        |
| 5a       | 3.22| 31.80        |
| 5b       | 3.06| 35.30        |
| 5c       | 3.19| 32.10        |
| 5d       | 1.63| 65.43        |
| 5e       | 3.06| 35.30        |
| 5f       | 3.29| 31.15        |
| Standard | 1.14| 75.80        |
| Control (Vehicle) | 4.71 |     |

Values are articulated in mean ± SE. n = 6 animals in each group E/F = Extension/Flexion [Decrease in ratio of extension phase (in seconds)/flexion phase (in seconds)], % Protection = (Control-test)/(Control) x 100

### Table 3. Neurotoxicity screening of the compounds

| Compound | Neurotoxicity screen |
|----------|---------------------|
|          | 0.5 h | 1 h | 2 h | 4 h |
| 3a       | 0/4   | 0/4 | 1/4 | 1/4 |
| 3b       | 0/4   | 0/4 | 0/4 | 0/4 |
| 3c       | 0/4   | 0/4 | 0/4 | 0/4 |
| 3d       | 0/4   | 0/4 | 0/4 | 0/4 |
| 3e       | 0/4   | 0/4 | 0/4 | 0/4 |
| 3f       | 0/4   | 0/4 | 0/4 | 0/4 |
| 5a       | 0/4   | 0/4 | 0/4 | 0/4 |
| 5b       | 0/4   | 0/4 | 0/4 | 0/4 |
| 5c       | 0/4   | 0/4 | 0/4 | 0/4 |
| 5d       | 0/4   | 0/4 | 0/4 | 0/4 |
| 5e       | 0/4   | 0/4 | 0/4 | 0/4 |
| 5f       | 0/4   | 0/4 | 1/4 | 1/4 |
| Standard | 0/4   | 0/4 | 0/4 | 0/4 |

The data in the table indicates the ratio of the no. of animals exhibiting neurotoxicity to the no. of animals tested.

3. Conclusions

In conclusion, synthesis of 1,2,4-triazole derivatives in good yield, characterized by spectral data. They were screened for anticonvulsant activity. Compounds 3b and 5d demonstrated good anticonvulsant activity without the significant neurological toxicity. The substituent on phenyl ring
influence on an anticonvulsant activity of tested 1,2,4-triazole derivatives. The additional modification and diversification of functional groups in order to improve the activity is currently in progress.

**Acknowledgements**

The Authors sincerely thank JSS Mahavidyapeeta, JSS College of Arts, Commerce and Science, Mysuru-25 and G Pulla Reddy College of Pharmacy, Mehdipatnam, Hyderabad-28, for providing research facilities to carry out this work.

4. **Experimental**

4.1. **Materials and methods**

Sigma Aldrich Chemicals limited bought all of the solvents and reagents. VMP III-Veego Melting Point apparatus had determined the melting range. The FT-IR spectra on Agilent FT-IR ATR Cary 630 using the spectral range of 7000–350 cm\(^{-1}\). \(^1\)H NMR spectra were registered using DMSO-d\(_6\) and internal standard as TMS on Bruker DRX-500 spectrometer at 400 MHz. \(^13\)C NMR spectra have been reported using DMSO-d\(_6\) and internal standard as TMS at 100 MHz Bruker DRX 500 spectrometer. The LC-MSD-Trap-XCT instrument was used for mass spectra.

4.2. **General procedure for 3a-f and 5a-f synthesis**

A mixture of 4-amino-4H-1,2,4-triazole (1) and substituted aldehydes (2a-f) and ketones (4a-f) in mortar mixed well. To the mixture, added a few drops of CH\(_3\)COOH. Using mortar and pestle, completely grounded the reaction mixture. The grinding continued for 3-4 hours (TLC controlled). For enough time at room temperature before moisture was extracted and eventually converted to dry powder. The resulting dry powdered yield was further transferred to water (25 mL) and diluted with HCl. Product was separated using filtration method and washed systematically with H\(_2\)O, dried, finally purification of unfinished product by crystallization from methanol and imines were obtained. Synthetic pathway imines of 3a-f and 5a-f are summarized in **Scheme 1** under solvent free condition.

\[
\text{N} \quad \text{N} \quad \text{N} \quad \text{NH}_2
\]

\[
\text{R-CHO, (2a-f)} \quad \text{H\textsuperscript{+}, 3-4 h} \quad \text{N} \quad \text{N} \quad \text{N} \quad \text{C} \quad \text{R}
\]

\[
\text{R\textsuperscript{1}-CO-CH}_3, (4a-f) \quad \text{H\textsuperscript{+}, 3-4 h} \quad \text{N} \quad \text{N} \quad \text{N} \quad \text{C} \quad \text{R\textsuperscript{1}} \quad \text{CH}_3
\]

**Scheme 1.** Synthetic pathway for the 1,2,4-triazole derivatives 3a-f and 5a-f.

4.3. **Physical and spectral data**

*Synthesis of 4-((4H-1,2,4-triazol-4-ylimino)methyl)-N,N-dimethylbenzenamine (3a)*
This compound was prepared using 4-amino-4H-1,2,4-triazole (1, 0.28 g, 0.003 mol) and 4-(dimethylamino)benzaldehyde (2a, 0.50 g, 0.003 mol). Mol. Formula: C_{11}H_{13}N_{5}, Mol. Wt.: 215.2, Yield (%): 66, UV-visible (λ_{max}): 420, Melting Point: 170 °C, Colour: Violet, Solubility: Methanol. FT-IR: ν: 3097 (Ar-H), 1640 (HC=N), 1529 (C=C), 1433 (N-N), 1159 (C-N). H NMR (DMSO-d_{6}, ppm): δ: 8.25 (s, 2H, Tri-H), 8.10 (s, 1H, CH), 7.35-7.34 (d, 2H, Ar-H, J = 4.0 Hz), 2.80 (s, 6H, 2CH_{3}). 13C NMR (DMSO-d_{6}, ppm): 158.0 (N=CH), 150.9 (Ar-C), 147 (Tri-C), 130.0, 123, 113.2 (Ar-C), 40.2 (N-CH_{3}). MS (M+) m/z: 215.

**Synthesis of (4-chlorophenyl)-N-(4H-1,2,4-triazol-4-yl)methanimine (3b)**

This compound was prepared using 4-amino-4H-1,2,4-triazole (1, 0.30 g, 0.003 mol) and 4-chlorobenzaldehyde (2b, 0.50 g, 0.003 mol). Mol. Formula: C_{9}H_{7}N_{4}Cl, Mol. Wt.: 206.6, Yield (%): 73, UV-visible (λ_{max}): 390, Melting Point: 210 °C, Colour: Off white, Solubility: Methanol. FT-IR: ν: 3069 (Ar-H), 1655 (HC=N), 1508 (C=C), 1471 (N-N), 1180 (C-N), 631 (C-Cl). H NMR (DMSO-d_{6}, ppm): δ: 8.75 (s, 2H, Tri-H), 8.40 (s, 1H, CH), 7.60-7.59 (d, 2H, Ar-H, J = 4.0 Hz), 13C NMR (DMSO-d_{6}, ppm): 157.5 (N=CH), 148.5 (Tri-C), 136.0, 131.5, 130.0, 128.5 (Ar-C). MS (M+) m/z: 206.

**Synthesis of (3,4-dimethoxyphenyl)-N-(4H-1,2,4-triazol-4-yl)methanimine (3c)**

This compound was prepared using 4-amino-4H-1,2,4-triazole (1, 0.25 g, 0.003 mol) and 3,4-dimethoxybenzaldehyde (2c, 0.50 g, 0.003 mol). Mol. Formula: C_{11}H_{12}N_{4}O_{2}, Mol. Wt.: 232.2, Yield (%): 50, UV-visible (λ_{max}): 320, Melting Point: 165 °C, Colour: Off white, Solubility: Methanol. FT-IR: ν: 3032 (Ar-H), 1620 (HC=N), 1496 (N-N), 1483 (C=C), 1375 (C-O), 1143 (C-N). H NMR (DMSO-d_{6}, ppm): δ: 8.30 (s, 2H, Tri-H), 3.80 (s, 6H, 2OCH_{3}). 13C NMR (DMSO-d_{6}, ppm): 157.0 (N=CH), 151.9 (Ar-C), 149.0 (Tri-C), 148.5, 127.0, 122.5, 115.0, 114.5 (Ar-C), 55.0 (OCH_{3}). MS (M+) m/z: 232.

**Synthesis of (3-methoxyphenyl)-N-(4H-1,2,4-triazol-4-yl)methanimine (3d)**

This compound was prepared using 4-amino-4H-1,2,4-triazole (1, 0.30 g, 0.003 mol) and 3-methoxybenzaldehyde (2d, 0.50 g, 0.003 mol). Mol. Formula: C_{10}H_{10}N_{4}O, Mol. Wt.: 202.0, Yield (%): 76, UV-visible (λ_{max}): 420, Melting Point: 122 °C, Colour: Violet, Solubility: Methanol. FT-IR: ν: 3097 (Ar-H), 1600 (HC=N), 1550 (C=C), 1483 (C-OCH_{3}), 1153 (C-N). 1H NMR (DMSO-d_{6}, ppm): δ: 8.30 (s, 2H, Tri-H), 6.80 (s, 1H, Ar-H), 3.75 (s, 3H, OCH_{3}). 13C NMR (DMSO-d_{6}, ppm): 160.0 (Ar-C), 157.0 (N=CH), 149.0 (Tri-C), 148.5, 127.0, 122.5, 115.0, 114.5 (Ar-C), 55.0 (OCH_{3}). MS (M+) m/z: 202.

**Synthesis of (3,4,5-trimethoxyphenyl)-N-(4H-1,2,4-triazol-4-yl)methanimine (3e)**

This compound was prepared using 4-amino-4H-1,2,4-triazole (1, 0.25 g, 0.003 mol) and 3,4,5-methoxybenzaldehyde (2e, 0.50 g, 0.003 mol). Mol. Formula: C_{12}H_{14}N_{4}O_{3}, Mol. Wt.: 262.0, Yield (%): 68, UV-visible (λ_{max}): 390, Melting Point: 143 °C, Colour: Off white, Solubility: Methanol. FT-IR: ν: 3032 (Ar-H), 1640 (HC=N), 1550 (N-N), 1483 (C=C), 1378 (C-OCH_{3}), 1153 (C-N). H NMR (DMSO-d_{6}, ppm): δ: 8.35 (s, 2H, Tri-H), 8.15 (s, 1H, CH), 6.65 (s, 2H, Ar-H), 3.75 (s, 3H, OCH_{3}). 13C NMR (DMSO-d_{6}, ppm): 156.0 (N=CH), 150.5 (Ar-C), 148.0 (Tri-C), 141.0, 128.0, 106.0 (Ar-C), 56.5 (OCH_{3}). MS (M+) m/z: 262.

**Synthesis of (2-nitrophenyl)-N-(4H-1,2,4-triazol-4-yl)methanimine (3f)**

This compound was prepared using 4-amino-4H-1,2,4-triazole (1, 0.28 g, 0.003 mol) and 2-nitro benzaldehyde (2f, 0.50 g, 0.003 mol). Mol. Formula: C_{9}H_{7}N_{5}O_{2}, Mol. Wt.: 217.5, Yield (%): 61, UV-visible (λ_{max}): 320, Melting Point: 110 °C, Colour: Off white, Solubility: Methanol. FT-IR: ν: 3097 (Ar-H), 1620 (HC=N), 1550 (N-N), 1529 (C=C), 1500 (C-NO_{2}), 1153 (C-N). H NMR (DMSO-d_{6}, ppm): δ:
Synthesis of 1-(4-ethoxyphenyl)-N-(4H-1,2,4-triazol-4-yl)ethanimine (5a)

This compound was prepared using 4-amino-4H-1,2,4-triazole (1, 0.26 g, 0.003 mol) and 1-(4-ethoxyphenyl)ethanone (4a, 0.50 g, 0.003 mol). Mol. Formula: C_{12}H_{14}N_{4}O, Mol. Wt.: 230.2, Yield (%): 65, UV-visible (λ_{max}): 460, Melting Point: 174 °C, Colour: Light blue, Solubility: Methanol. FT-IR: ν 3090 (Ar-H), 1630 (HC=N), 1529 (C=C), 1430 (N-N), 1159 (C-N), 1050 (C-O). 1H NMR (DMSO-d6, ppm) δ: 8.30 (s, 2H, Tri-H), 7.50-7.49 (d, 2H, Ar-H, J = 4.0 Hz), 6.80-6.79 (d, 2H, Ar-H, J = 4.0 Hz), 3.95 (q, 2H, CH₂), 1.30-1.28 (t, 3H, CH₃, J = 8.0 Hz), 0.95 (s, 3H, CH₃). 13C NMR (DMSO-d6, ppm): 164.7 (C=N), 159.8 (Ar-C), 148.0 (Tri-C), 128.8, 125.6, 114.2 (Ar-C), 64.7 (CH₂), 19.5 (CH₃), 14.8 (CH₃). MS (M+) m/z: 230.

Synthesis of 1-(pyridin-2-yl)-N-(4H-1,2,4-triazol-4-yl)ethanimine (5b)

This compound was prepared using 4-amino-4H-1,2,4-triazole (1, 0.34 g, 0.004 mol) and 1-(pyridin-2-yl)ethanone (4b, 0.50 g, 0.004 mol). Mol. Formula: C₉H₉N₅, Mol. Wt.: 187.3, Yield (%): 65, UV-visible (λ_{max}): 480, Melting Point: 152 °C, Colour: Light blue, Solubility: Methanol. FT-IR: ν 3090 (Ar-H), 1620 (HC=N), 1529 (C=C), 1491 (Pyr C=N), 1430 (N-N), 1158 (C-N). 1H NMR (DMSO-d6, ppm) δ: 8.80 (d, 1H, Pyr-H, J = 4.0 Hz), 8.35 (s, 2H, Tri-H), 8.00 (d, 1H, Pyr-H, J = 4.0 Hz), 7.90-7.62 (m, 2H, Pyr-H), 0.90 (s, 3H, CH₃). 13C NMR (DMSO-d6, ppm): 164.0 (C=N), 154.0, 149.1 (Ar-C), 148.5 (Tri-C), 136.1, 126.2, 123.9 (Ar-C), 13.5 (CH₃). MS (M+) m/z: 187.

Synthesis of 3-(1-(4H-1,2,4-triazol-4ylimino)ethyl)benzonitrile (5c)

This compound was prepared using 4-amino-4H-1,2,4-triazole (1, 0.29 g, 0.003 mol) and 3-acetylbenzonitrile (4c, 0.50 g, 0.003 mol). Mol. Formula: C_{11}H_{9}N_{5}, Mol. Wt.: 211.2, Yield (%): 55, UV-visible (λ_{max}): 500, Melting Point: 160 °C, Colour: Green, Solubility: Methanol. FT-IR: ν 3095 (Ar-H), 2360 (C≡N), 1625 (HC=N), 1529 (C=C), 1430 (N-N), 1150 (C-N). 1H NMR (DMSO-d6, ppm) δ: 8.20 (s, 2H, Tri-H), 7.90 (s, 1H, Ar-H), 7.85-7.50 (m, 3H, Ar-H), 0.90 (s, 3H, CH₃). 13C NMR (DMSO-d6, ppm): 163.0 (C≡N), 147.5 (Tri-C), 134.5, 133.5, 131.5, 129.6, 112.7 (Ar-C), 115.8 (C≡N), 13.0 (CH₃). MS (M+) m/z: 211.

Synthesis of 1-(1H-indol-4-yl)-N-(4H-1,2,4-triazol-4-yl)ethanimine (5d)

This compound was prepared using 4-amino-4H-1,2,4-triazole (1, 0.26 g, 0.003 mol) and 1-(1H-indol-3-yl)ethanone (4d, 0.50 g, 0.003 mol). Mol. Formula: C_{12}H_{11}N₅, Mol. Wt.: 225.3, Yield (%): 67, UV-visible (λ_{max}): 490, Melting Point: 157 °C, Colour: Light blue, Solubility: Methanol. FT-IR: ν 3095 (Ar-H), 2360 (C≡N), 1655 (HC=N), 1509 (C=C), 1470 (N-N), 1181 (C-N). 1H NMR (DMSO-d6, ppm) δ: 10.80 (s, 1H, NH), 8.29 (s, 2H, Tri-H), 7.50-7.49 (d, 1H, Ar-H, J = 4.0 Hz), 7.23-7.22 (d, 1H, Ar-H, J = 4.0 Hz), 6.95 (t, 1H, Ar-H), 6.40-6.38 (d, 1H, Indole-H, J = 8.0 Hz), 6.10-6.08 (d, 1H, Indole-H, , J = 8.0 Hz ), 0.95 (s, 3H, CH₃). 13C NMR (DMSO-d6, ppm): 162.0 (C≡N), 147.5 (Tri-C), 134.5, 133.5, 131.5, 129.6, 112.7 (Ar-C), 115.8 (C≡N), 13.0 (CH₃). MS (M+) m/z: 225.

Synthesis of 1-(pyridin-3-yl)-N-(4H-1,2,4-triazol-4-yl)ethanimine (5e)

This compound was prepared using 4-amino-4H-1,2,4-triazole (1, 0.34 g, 0.004 mol) and 1-(pyridin-3-yl)ethanone (4e, 0.50 g, 0.004 mol). Mol. Formula: C₉H₉N₅, Mol. Wt.: 187.2, Yield (%): 65, UV-visible (λ_{max}): 480, Melting Point: 152 °C, Colour: Light blue, Solubility: Methanol. FT-IR: ν 3090 (Ar-H), 1620 (HC=N), 1529 (C=C), 1491 (Pyr C=N), 1430 (N-N), 1158 (C-N). 1H NMR (DMSO-d6, ppm) δ: 9.20 (s, 1H, Pyr-H), 8.80-8.79 (d, 1H, Pyr-H, J = 4.0 Hz), 8.35-8.34 (d, 1H, Pyr-H, J = 4.0 Hz), 8.25 (s, 2H, Tri-H), 7.65-7.63 (t, 1H, Pyr-H, J = 8.0 Hz), 0.95 (s, 3H, CH₃). 13C NMR (DMSO-d6, ppm):
164.0 (C=N), 154.0, 149.1 (Ar-C), 148.0 (Tri-C), 136.5, 126.1, 123.8 (Ar-C), 13.5 (CH₃). MS (M⁺) m/z: 187.

**Synthesis of 1-(naphthalen-2-yl)-N-(4H-1,2,4-triazol-4-yl)ethanimine (5f)**

This compound was prepared using 4-amino-4H-1,2,4-triazole (1, 0.25 g, 0.003 mol) and 1-(naphthalen-2-yl)ethanone (4f, 0.50 g, 0.003 mol). Mol. Formula: C₁₄H₁₂N₄, Mol. Wt.: 236.3, Yield (%): 62, UV-visible (λmax): 440, Melting Point: 140 °C, Colour: Light blue, Solubility: Methanol. FT-IR: ν₃₀₈₀ (Ar-H), 1625 (HC=N), 1528 (C=C), 1430 (N-N), 1158 (C-N). ¹H NMR (DMSO-d₆, ppm) δ: 8.35 (s, 1H, Ar-H), 8.25 (s, 2H, Tri-H), 7.95-7.94 (d, 1H, Ar-H, J = 4.0 Hz), 7.85-7.84 (d, 1H, Ar-H, J = 4.0 Hz), 7.60-7.30 (m, 4H, Ar-H), 0.90 (s, 3H, CH₃). ¹³C NMR (DMSO-d₆, ppm): 163.0 (C=N), 148.0 (Tri-C), 136.1, 133.5, 128.6, 128.2, 128.1, 126.9, 127.3, 126.2, 126.1 (Ar-C), 16.5 (CH₃). MS (M⁺) m/z: 236.

**4.4. Anticonvulsant activity**

Male Wistar rats (190-220 g) and mice (19-20 g) procured from National Institute of Nutrition, Hyderabad (190-220 g) were used in the present study. The animals were kept in individual cages for 1 week to acclimatize for the laboratory conditions. They were allowed to free access of water and food. All the experimental procedures were carried out in accordance with Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA) guidelines. The study was reviewed and approved by the Institutional Animal Ethics Committee, G Pulla Reddy College of Pharmacy, Hyderabad, India.

**Maximal electroshock seizure model (MES)**

MES seizure model was used in the present study to evaluate the anticonvulsant activity of the compounds on male Wistar rats.¹⁹ Seizures were induced in rats by delivering electro shock of 150mA for 0.2 s by means of a convulsiometer through a pair of ear clip electrodes. The test compounds (100 mg/kg) were administered by oral route in the form of solution (the compounds were dissolved in 1% sodium carboxy methyl cellulose), 30 min before the MES seizure test. The animals were observed closely for 2 min (noted tonic flexion (F) and extension (E) phases in seconds). The percentage of inhibition of seizure relative to control was recorded and calculated. Phenytoin (100 mg/kg) was used as a standard drug.

**Neurotoxicity screening**

The minimal motor impairment was measured in mice by the rotorod test.¹⁹ The mice were trained to stay on the accelerating rotorod that rotates at 10 revolutions per minute. The rod diameter was 3.2 cm. Trained animals were administered with the test compounds at a dose of 100 mg/kg by oral route. Neurotoxicity was indicated by the inability of the animal to maintain equilibrium on the rod for at least 1 min in each of the three trials. Phenytoin was used as a standard drug.

**References**

1. Paronikyan E. G., Noravyan A. S., Dzhagatspanyan I. A., and Nazaryan I. M. (2002) Synthesis and anticonvulsant activity of isothiazolo[5,4-b]pyrano(thiopyrano)[4,3-d]pyridine and isothiazolo[4,5-b]-2,7-naphthyridine derivatives. Pharm. Chem. J., 36 (9) 465-467.

2. Saini M.S., and Dwivedi J. (2013) Synthesis and biological significances of 1, 2, 4-triazole and its derivatives: A review. Int. J. Pharm. Sci. Res., 4 (8) 2866-2879.
3. Bahceci S., Yuksek H., Ocak Z., Koksal C. M., and Ozdemir. (2002) Synthesis and non-aqueous medium titrations of some new 4,5-dihydro-1H-1,2,4-triazol-5-one derivatives. *Acta Chim. Slov.*, 49 783-794.

4. Zhang J., Redman N., Litke A. P., Zeng J., Zhan K., Chan K. Y., and Chan C. T. (2011) Synthesis and antibacterial activity study of a novel class of cationic anthraquinone analogs. *Bioorg. Med. Chem.*, 19 (1) 498-503.

5. Shehry M. F., Abu-Hashem A., and El-Telbani E. M. (2010) Synthesis of 3-((2,4-dichlorophenoxymethyl)-1,2,4-triazolo(thiadiazoles and thiadiazines) as anti-inflammatory and molluscicidal agents. *Eur. J. Med. Chem.*, 45 (5) 1906-1911.

6. Siddiqui N., and Ahsan W. (2010) Triazole incorporated thiazoles as a new class of anticonvulsants: design, synthesis and in vivo screening. *Eur. J. Med. Chem.*, 45 (4) 1536-1543.

7. Yan S., Liu Y., Chen Y., Liu L., and Lin J. (2010) An efficient one-pot synthesis of heterocycle-fused 1,2,3-triazole derivatives as anti-cancer agents. *Bioorg. Med. Chem. Lett.*, 20 (17) 5225-5228.

8. Patel N. B., Khan I. H., and Rajani S. D. (2010) Pharmacological evaluation and characterizations of newly synthesized 1,2,4-triazoles. *Eur. J. Med. Chem.*, 45 (9) 4293-4299.

9. Diwedi R., Alexandar S., and Chandrashekar M. J. N. (2011) Rapid and efficient synthesis of microwave assisted some bis-1, 2, 4-triazole derivatives and their antioxidant and anti-inflammatory evaluation. *Res. J. Pharm., Biol. Chem. Sci.*, 2 (1) 194-204.

10. Qadir M.A., Ahmed M., Aslam H., Waseem S., and Shafiq M. I. (2015) Amidine sulfonamides and benzene sulfonamides: Synthesis and their biological evaluation. *J. Chem.*, 2015 1-8.

11. Raman N., Kulandaisamy A., Shunmugasundaram A., and Jeyasubramaniam K. (2001) Redox and antimicrobial studies of transition metal(II) tetradentate Schiff base complexes. *Transition Met. Chem.*, 26 131-135.

12. Nagashree S., Mallu P., Mallesha L., and Bindya S. (2013) Synthesis, characterization and antimicrobial activity of methyl-2-aminopyridine-4-carboxylate derivatives. *J. Chem.*, 2013, 1-5.

13. Tanaka K., Shimoura R., and Caira M. R. (2010) Synthesis, crystal structures and photochromic properties of novel chiral Schiff base macrocycles. *Tetrahedron Lett.*, 51 (2) 449-452.

14. Devasagayam T. P. A., Tilak J. C., and Boloor K. K. (2004) Review: free radical and antioxidants in human health. *Curr. Stat. Fut. Pros.*, 53 794-804.

15. Bauer J., and Reuber M. (2003) Medical treatment of epilepsy. *Expert Opin. Emerg. Drugs*, 8 (2) 457-467.

16. Daniel J. B., Joao P. C., Maria L. B., and Felix C. (2015) *In vitro* models for neurotoxicology research. *Toxi. Res.*, 4 801-842.

17. Prasanna kumar B. N., Mohana K. N., and Mallesha L. (2014) Synthesis, characterization and *in vitro* antimicrobial evaluation of new 5- chloro-8- bromo-3-aryl-1,2,4-triazolo[4,3-c]pyrimidines. *Med. Chem. Res.*, 23 445-453.

18. Hossein H., and Marjan N. A. (2003) Anticonvulsant, sedative and muscle relaxant effects of carbadoxolone in mice. *BMC Pharm.*, 3 1-6.

19. Kumar C. S. A., Veeresh B., Ramesha K. C., Raj C. S. A., Mahadevaiah K. M., and Prasad S. B. B. (2017) Synthesis and evaluation of novel diazaspiro hydantoins as potential anticonvulsants. *Cent. Nerv. Syst. Agents Med. Chem.*, 17 (3) 201-208.